A Worker Adjustment and Retraining Notification Act notice of the layoffs was filed Friday with the
The latest round of layoffs at 454 Life Sciences are part of an elimination of the Roche's Applied Science Division in order to enhance the company's overall responsiveness to scientific and market needs, company officials have said. Products being developed by the Applied Science Division will be integrated into the portfolios of other parts of the company.
454 Life Sciences, which specializes in developing and commercializing genome sequencer systems to analyze DNA, currently employs about 130 employees,
"The current 454 sequencing systems will be phased-out in mid-2016," Moita said. "That means that manufacturing will be concluded in 2015 and we continue to support the current systems until mid-2016. 454 Life Sciences is committed to finding socially responsible solutions for the employees affected by these changes including potential transfers to other sites."
The layoffs and closing of 454 Life Sciences represent a setback for the
454 Life Sciences was established as part of fellow biotech company
(c)2013 the New Haven Register (New Haven, Conn.)
Visit the New Haven Register (New Haven, Conn.) at www.nhregister.com
Distributed by MCT Information Services
Original headline: Drug giant Roche to lay off more workers